Within the TCGA prostate cancer cohort (Cerami et al., 2012; Gao et al., 2013; Cancer Genome Atlas Research Network, 2015), we find that FOXI3 expression increases with tumor stage (Figure 3A). Here, FOXI3 is linked to prostate carcinoma.